Peter Black, MD, discusses which patients are currently eligible for immunotherapy, how the indications are likely to expand, some of the common side effects of immunotherapy and their incidence, and the availability of tools to determine which patients are suitable candidates for treatment.
In this interview, Steven A. Kaplan, MD, highlights the key updates to the 2018 guideline that differentiates it from the AUA’s 2010 guideline on this topic.
Robert A. Dowling, MD, shares the experiences of two practices that have recently embarked on the EHR transition journey and discuss the lessons they learned and how to apply them to your own situation.
Attorneys will scour for online ‘dirt’ to use in a lawsuit, writes Brianne Goodwin, JD, RN.
Statin use by patients with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy may increase overall survival and prostate cancer-specific survival.
A private urology practice can successfully transform itself from a fee-for-service payment model for cancer care to an episode-based system, although it remains to be determined whether operating under this model also translates into cost savings.
“Patients should be informed of the less-than-ideal stone-free rates and secondary morbidity when residual fragments are present after this treatment modality,” says researcher Igor Sorokin, MD.
The decline occurred despite a consistent number of monthly clinical encounters with a primary diagnosis of hypogonadism.
The analysis “gives urologists the first accurate idea of how many physician assistants and nurse practitioners are working in urology,” says researcher Raymond Fang.
New study findings provide evidence to guide management decisions for patients with prostate cancer who have lymph node metastases following radical prostatectomy.